Discover 1,099 paid clinical trials in New Haven, Connecticut. Search by condition or phase to find a research study near you that matches your needs across various therapeutic areas.
Filter
2
Filter results
Results: 1,099
Active & Responsive
A Study of PARG Inhibitor IDE161 in Participants With Advanced Solid Tumors
for
Advanced or Metastatic Solid Tumors, Breast Cancer,
Location: 21 recruiting locations
Sponsor: IDEAYA Biosciences
Sex: All
Age: 18+
Code: NCT05787587
Phase1, Recruiting
Active & Responsive
Pharmacological and Behavioral Treatment After Bariatric Surgery: Acute (Stage 1)
for
Loss-of-control Eating, Obesity/Overweight
Location: 1 recruiting location
Sponsor: Yale University
Sex: All
Age: 18 - 70
Code: NCT04599478
Phase2, Phase3, Recruiting
Active & Responsive
Comparison of Anti-coagulation and Anti-Platelet Therapies for Intracranial Vascular Atherostenosis
for
Intracranial Arteriosclerosis, Stroke
Location: 77 recruiting locations
Sponsor: University of Florida
Sex: All
Age: 30+
Code: NCT05047172
Phase3, Recruiting
Active & Responsive
A Study of a Potential Disease Modifying Treatment in Individuals at Risk for or With a Type of Early Onset AD Caused by a Genetic Mutation
First-in-Human Study of Mutant-selective PI3Kα Inhibitor, RLY-2608, as a Single Agent in Patients With Advanced Solid Tumors and in Combination With Endocrine Therapy +/- a CDK4/6 or CDK4 Inhibitor in Patients With Advanced Solid Tumors or Advanced Breast Cancer
for
PIK3CA Mutation, Solid Tumor, Adult,
Location: 19 recruiting locations
Sponsor: Relay Therapeutics, Inc.
Sex: All
Age: 18+
Code: NCT05216432
Phase1, Recruiting
Active & Responsive
A Study to Evaluate Safety, Pharmacokinetics, and Activity of GDC-7035 as a Single Agent and in Combination in Patients With Advanced Solid Tumors
for
Solid Tumor
Location: 13 recruiting locations
Sponsor: Genentech, Inc.
Sex: All
Age: 18+
Code: NCT06619587
Phase1, Recruiting
Active & Responsive
FOG-001 in Locally Advanced or Metastatic Solid Tumors
for
Cancer, Colorectal Cancer, Solid Tumor,
Location: 18 recruiting locations
Sponsor: Parabilis Medicines, Inc.
Sex: All
Age: 18+
Code: NCT05919264
Phase1, Phase2, Recruiting
Active & Responsive
A Phase II Evaluation of Afatinib in Patients With Persistent or Recurrent HER2-positive Uterine Serous Carcinoma